Antibody-Drug Conjugate Linker-Payload Design for Selective Cancer Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including antibody-drug conjugates (ADCs), face challenges in effectively targeting and delivering cytotoxic payloads to cancer cells, necessitating the development of more potent and selective therapeutic agents.
Innovation Solution
Development of novel antibody-drug conjugates (ADCs) with specific compounds of Formula (I) and (IA) that enhance the delivery and release of cytotoxic payloads to targeted cancer cells, utilizing diverse linkers and substituents to improve potency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody-drug conjugates are used to deliver cytotoxic payloads to cancer cells, then targeted delivery is achieved, but the potency and therapeutic window are limited
Solution Approach 1:
The patent modifies the chemical structure of the cytotoxic payload through specific molecular formulas (Formula I and IA) with varied substituents and linkers, changing the pharmacological parameters to achieve enhanced potency while maintaining targeted delivery, thus expanding the therapeutic window
Solution Approach 2:
The invention creates a composite structure combining the monoclonal antibody component with the novel cytotoxic compound through a linker, forming an ADC with optimized properties that achieve both targeted delivery and enhanced cell-killing potency
2Object-affected harmful factors
If current ADC designs are used, then cancer cell targeting is achieved, but selectivity and potency are insufficient
Solution Approach 1:
The patent introduces specific local chemical modifications to the ADC structure, including particular linker configurations and substituent patterns in Formula (I) and (IA), that enhance the local interaction with cancer cell targets while maintaining overall selectivity
Solution Approach 2:
The ADC is segmented into distinct functional components (antibody, linker, cytotoxic payload) that can be independently optimized, allowing the cytotoxic portion to be maximized for potency while the antibody and linker ensure selective targeting
Data Source
AI summary
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. Additionally, provided herein are functionalized compounds, for example, a compound of Formula (IA), for conjugation with an antibody.